ANDRZEJEWSKI STEPHEN J 4/A
4/A · KING PHARMACEUTICALS INC · Filed Jan 22, 2009
Insider Transaction Report
Form 4/AAmended
ANDRZEJEWSKI STEPHEN J
Chief Commercial Officer
Transactions
- Exercise/Conversion
Common Stock
2008-12-31+21,060→ 142,720 total - Award
Common Stock
2009-01-16+3,823→ 146,543 total - Exercise/Conversion
Long-Term Performance Unit
2008-12-31−21,060→ 0 totalExp: 2008-12-31→ Common Stock (21,060 underlying)
Footnotes (2)
- [F1]Represents shares of common stock earned in connection with Long-Term Performance Units that provided for a contingent right to receive shares of King Pharmaceuticals, Inc. common stock based upon the Company's total shareholder return, relative to the Dow Jones Pharmaceutical Index, for the period January 1, 2006 through December 31, 2008.
- [F2]Each Long-Term Performance Unit represented a contingent right to receive a share of King Pharmaceuticals, Inc. common stock if the reporting person remained employed by King Pharmaceuticals, Inc. during the two-year vesting period that ended on December 31, 2008.